REVIEW ARTICLE   **OPEN ACCESS**

A Brief Review on Artificial Intelligence in Pharmacology

Jyoti Jawale, Diksha Shinde*, Shalaka Kunjir, Sejal Dorage, Shraddha Randhwan, Shraddha Tapkir, Shrungar Randhir, Sayali Gaikwad, Shivani Kholam
DKSS Institute of Pharmaceutical Science and Research (For Girls), Swami-Chincholi, Bhigwan
*Corresponding Author:dikshashinde3030@gmail.com

ABSTRACT
Artificial Intelligence (AI) is now used throughout the entire continuum of pharmacology research and clinical practice and from early drug discovery to real-world datamining. The types of AI models used range from unsupervised clustering of drugs or patients aimed at identifying potential drug compounds or suitable patient populations, to supervised machine learning approaches to improve therapeutic drug monitoring. Additionally, natural language processing is increasingly used to mine electronic health records to obtain real-world field. AI is already successfully applied in drug discovery and target identification for several years. More recently AI models which help to characterize patient populations and predict an individual's drug response are emerging, thereby covering the entire pipeline from drug discovery to personalized medicine. In 2020, the use of AI in clinical pharmacology was extensively discussed Many of these applications are still used and relevant. However, there have been many new developments since. In this, we will discuss the current application of different AI and Machine Learning (ML) approaches in the field of pharmacology. Recently, artificial intelligence (AI) has become well known for being used in a variety of pharmaceutical science domains, including pharmacological research. Preclinical (lab animals) and clinical (in humans) trial data analysis is aided by it. Additionally, AI is crucial for a number of procedures, including drug development and manufacture, big data disease detection, personalized treatment, clinical trial research, radiation, surgical robotics, smart electronic health records, and epidemic outbreak prediction. Recently, artificial intelligence (AI) has become well known for being used in a variety of pharmaceutical science domains, including pharmacological research. Preclinical (lab animals) and clinical (in humans) trial data analysis is aided by it. Various operations, including drug discovery and manufacturing, large data analysis for disease identification, and other activities, also greatly benefit from AI the use of smart electronic health records, radiation, robotic surgery, clinical trial research, and the prediction of disease outbreaks. In this, we will discuss the current application of different AI and ML approaches in the field of pharmacology.
Keywords: Artificial Intelligence, Pharmacology, Machine Learning, Clinical study, Preclinical study

INTRODUCTION

A subfield of computer science called artificial intelligence is capable of assessing intricate medical data. Their ability to find significant relationships in a data collection can be employed in various clinical situations for diagnosis, therapy, and outcome prediction.

The field of science and technology known as artificial intelligence (AI) is nascent. At all societal levels, from individuals to social organizations, corporations, and governments, it already has an impact on a variety of human activities. In almost every industrial, economic, and societal sector, including information technologies, manufacturing, space, remote sensing, security and defense, transportation and vehicles, and, since the turn of the century, medicine and health care, AI has been rapidly expanding. [1,2]

Tools of ever-greater sophistication have been created throughout many ages to benefit the human race. In many ways, digital computers are just another tool. They are capable of performing the same types of numerical and symbolic manipulations as a regular person, but more quickly and accurately. The question of whether we can create a computer (or computer programme) that can think is more intriguing. [3] As Penrose (1989) has noted, the majority of us are fairly content with devices that allow us to perform physical tasks more swiftly or effortlessly, such as driving down a motorway or digging. [4] We are also content to employ tools that let us perform physical tasks that would be otherwise impossible, like flying. However, the concept of a machine that can think for us is a significant advancement in our aspirations and one that raises numerous ethical and philosophical issues. The goal of artificial intelligence (AI) research is to create such a computer and to better understand intelligence. The science behind computer systems that replicate human thinking processes is known as artificial intelligence. Building a machine that can duplicate or outperform human mental talents, including thinking, understanding, imagination,

perception, recognition, creativity, and emotions, would be the field's pinnacle achievement. Even while we are still far from accomplishing this, we have had some very significant victories. A family of incredibly practical computing tools has been created as a result of artificial intelligence research, which is maybe even more significant than these small triumphs.

These tools have made it possible to solve many issues that were previously thought to be insurmountable and to solve many other problems more successfully. From a practical standpoint, this alone makes them intriguing and valuable. [6]

The following major categories can be used to generally classify AI tools:

Artificial intelligence (CI), which is implicit modeling with numerical approaches; knowledge-based systems (KBSs), which are explicit models utilizing words and symbols. Techniques including rule-based, model-based, frame-based, and case-based reasoning fall within the first category. The knowledge can be read and comprehended by humans since it is explicitly modeled in words and symbols. Although symbolic techniques have unquestionably been successful in their own fields, they are inherently restricted in that they can only deal with circumstances that have been modeled explicitly. Despite the fact that some methods permit the model to grow Symbolic representations are typically bad at coping with the unfamiliar.[7]


Figure 1- Categories of Intelligent system software

According to John McCarty, the father of artificial intelligence, artificial intelligence is the study of utilizing computer programs to make machines intelligent. The AI claims that "Today's Science is Tomorrow's Technology," which indicates that all humans must assert their presence while utilizing technical knowledge in order to survive. [8]

When do we refer to AI?

The term artificial intelligence (AI) is used when a human-made computer simulates some functions so that many human minds come together to solve a problem and learn something.

The term "Medical Technology" is frequently used to refer to a variety of tools that can help medical professionals diagnose patients earlier, prevent complications, optimize treatment and/or offer less invasive options, and shorten hospital stays for patients and society as a whole. Prior to the advent of smartphones, wearables, sensors, and communication systems, medical technologies were primarily known as traditional medical devices (such as prosthetics, stents, and implants). [9] However, the development of smartphones, wearables, sensors, and communication systems has revolutionized medicine by allowing the inclusion of artificial intelligence (AI) powered tools. (For example, programs) in incredibly tiny sizes. Medical technology has undergone a revolution thanks to artificial intelligence (AI), which is generally regarded as the domain of computer science that can handle difficult issues with a wide range of applications in fields with vast amounts of data but little theory. [2]

**Figure 2- Sectors in Artificial Intelligence**

Figure 3- Application of AI in various branches of Science

The general public has embraced intelligent medical technologies (i.e., AI-powered ones) in part because they enable the 4P model of medicine (Predictive, Preventive, Personalized, and Participatory) and, consequently, patient autonomy, in ways that were previously impossible. [3] For example, smartphones are increasingly being used to fill out and distribute electronic personal health records [4], monitor vital functions with biosensors [5], and support remote patient monitoring. The rise of augmented medicine, or the application of modern medical technology to enhance different areas of clinical practice, is made possible by the development of intelligent medical technologies. The Food and Drug Administration (FDA) has approved several AI-based algorithms in the last ten years; as a result, they could be used. Several other digital tools, such as surgical navigation systems for computer-assisted surgery [7], virtuality-reality continuum tools for surgery, pain management, and mental diseases, as well as AI-based technologies, enable augmented medicine. [10] Despite the fact that the field of augmented medicine appears to be a success with patients, it can run into some opposition from medical professionals, especially doctors. To explain this phenomenon, four frequently cited explanations should be given. First, a clear absence of fundamental and ongoing training in this field contributes to under-preparedness for

the promise of digital medicine. [11] Second, early healthcare process digitization was significantly different from the promise of augmented medicine in that it was accompanied by a sharp increase in administrative burden, primarily associated with electronic health records [12], which is today recognized as one of the primary causes of physician burnout. Third, despite the present and widespread belief in the literature that AI will eventually complement physician intelligence [13, 14], there is growing concern that doctors could be replaced by machines [15]. Fourth, the use of AI by doctors exposes them to potential legal repercussions because there is currently no global legal framework that establishes liability in the adoption or rejection of algorithm recommendations.

The essence of practicing medicine has been obtaining as much data about the patient's health or disease as possible and making decisions based on that. Physicians have had to rely on their experience, judgement, and problem-solving skills while using rudimentary tools and limited resources, With the cultural transformation called digital health, disruptive technologies have started to make advanced methods available not only to medical professionals but also to their patients. [16]

The core of medical practice has always been gathering as much information as possible about the patient's health or illness and making judgments based on that information. Using crude instruments and scant resources, doctors have had to rely on their knowledge, judgment, and problem-solving abilities.

Disruptive technologies have begun to make cutting-edge techniques accessible to patients as well as medical professionals thanks to the cultural shift known as digital health. Wearable sensors, biotechnology, and artificial intelligence (AI) are a few examples of the technologies that are increasingly pointing in three main directions. They have been (1) turning the patient into the focal center of care, (2) generating enormous amounts of data that demand sophisticated analytics, and (3) laying the groundwork for precision medicine. Medicine has evolved toward prevention, personalisation, and precision rather than developing therapies for populations and making the same medical decisions based on a few similar physical traits among patients. AI is the primary technology in this shift and cultural transformation that can help people take advantage of this potential in their daily lives.

We began to question if human doctors might eventually be replaced by AI tools in the healthcare industry as a result of recent advancements in AI technology. Practically speaking, AI tools may not be able to completely replace human doctors, but they can help them get better outcomes and more accuracy in the medical setting. The availability of healthcare data is a key factor supporting the development of AI solutions in the medical industry.

A group of technologies make up artificial intelligence, which is more than simply one technology. Some of these technologies, like machine learning, are frequently used in healthcare. Machine learning is a method where models are trained using preexisting data so that when someone feeds the data you are using for testing, it will recognize the test input based on prelearning. One of the most popular types of artificial intelligence is machine learning. [17]

Precision medicine is where machine learning is utilized in healthcare the most frequently. Precision medicine makes predictions about which treatment plans will be effective for a certain patient based on patient data from the past. [1] In order to determine from prior learning, the model must be trained using datasets; this process is known as supervised learning. Figure 1 illustrates some applications of AI in pharmacy and healthcare. [17]

Applications of AI in ADMET predictions:

As AI tools have become more prevalent, in silico assessments of absorption, distribution, metabolism, excretion, and tolerated toxicity (ADMET) have advanced significantly. As a result, more accurate models have been created. Methods like DNNs, ANNs, RFs, and SVMs, as well as k-NN, have paved the way in this sector with good performance, but there are still a number of variables to take into account, such as encoding functions, the volume and calibre of input data, and many more. According to various research, intestinal medication absorption has one of the highest influences on bioavailability and is accurate with an acceptable range. On a dataset with 104 and 26 molecules (the training and test sets, respectively), a novel hierarchical SVM scheme was created to predict the colon cancer cell layer (Caco-2); the model had outstanding qualitative performance and revealed great accuracy. Prior to that, DNN architecture. However, a number of aspects need be taken into account, such as encoding functions, the quantity and quality of input data. Techniques like DNNs, ANNs, RFs and SVMs, and k-NN have opened a wide avenue in this subject with good results. One of the factors that most affects bioavailability is intestinal medication absorption, which various studies have proven for accuracy with a tolerable range. [18] A novel hierarchical SVM strategy was created to predict the Caco-2 cell layer of colon cancer using datasets including 104 and 26 molecules, respectively (training and test set). The model had outstanding qualitative performance and revealed great accuracy. Previously, a DNN architecture was suggested employing 209 molecular descriptors and shown good discriminant power for the prediction of cellular permeability in compound-derived Caco-2 cell lines. . Four approaches were integrated in a bigger dataset

(1272 chemicals) to predict permeability, including boosting, partial least-squares PLS, SVM, and MLR. The boosting model was the most effective and had the highest Q2, RMSE, CV, and R2 values. A important pharmacokinetic factor that affects the medication volume distribution is plasma protein binding (PPB). Predictive models have been constructed using heterogeneous data in silico due to the time-consuming and expensive nature of conventional tests. When predicting the PPB values of cyclic peptides using two algorithms (forward beam search and enumerating lasso solutions), the ELS was more reliable in predicting a wide range of molecules with strong generalisation ability. The authors of a study presented six models (SVM, ANN, k-NN, PLS, Probabilistic neural network, Linear discriminant analysis) in a dataset of 736 compounds. While all methods were highly effective at binary classification and PPB prediction, SVM showed the best accuracy, sensitivity, specificity, precision, and F1 score. Prediction models have also been developed in order to learn more about other natural barriers that affect drug distribution, such as the blood-brain barrier (BBB). [19] The accuracy and specificity scores of the proposed DL-based RNN to predict chemical penetration to the CNS were 96.53% and 98.08%, respectively; the dataset included compounds encoded in SMILES (1803 BBB+ and 547 BBB substances). To predict the BBB ability of marine-derived kinase inhibitors, multiple binary classifiers and logistic regression were developed (18 models). The accuracy of RF, gradient boosting, and logistic regression was the top-performing model. In a nutshell, the broad range of applications for AI methods can lighten the workload of several clinical studies for medication distribution research. There have been numerous investigations of AI in the subject of metabolism predictions to look into the locations of metabolism, the isoforms responsible for the process, and metabolic pharmacokinetics and pharmacodynamics (drug-drug interactions). To predict protein subcellular localization from the dataset retrieved from the UniProt database, DeepLoc (DNN-based model) has been provided; in the independent test set, the accuracy obtained was highest (compared to other methods: LocTree2, MultiLoc2, MultiLoc2, YLoc, CELLO, iLocEuk, WoLF PSORT).Use of the Laplacian-modified naive Bayesian technique to classify the effectiveness of 4500 substances as inhibitors of five CYP isoforms Moreover, five network-based label space division (NLSD)-based approaches, twin SVMs, and multilabel kNNs were used to explore the substrate selectivity of the CYP450 enzyme using a dataset of 484 chemicals and 1299 compound/isoform pairs; reached NLSD-XGB.the best results using the HO and CV approaches. A study that examined the interaction between CYP inhibitors and their ability to inhibit CYP provided a Super CYPsPred web server based on the RF algorithm that was focused on five CYP isoenzymes and contained 17 143 compounds. To discover pharmacological interactions with G-protein coupled receptors (GPCRs), a new sequencing technique based on distance-weighted kNN has been proposed.A study used the BIOiSIM platform's integrated coarse-tuning and fine-tuning algorithms to predict drug exposure (AUC, Cmax, and Tmax).Recently, there has been an increase in the creation of AI-based excretion predictors to study the paths for clearance. CPathPred, a recently developed SVM-based predictor on a dataset of 141 authorised pharmaceuticals, has boosted the ease of molecular descriptors and major clearance pathways.Total plasma clearance (Cltot) of 1114 compounds was determined by StarDrop using eight different techniques (PLS, radial basis function fitting (RBF), RF, Gaussian process models (GP) with two-dimensional search for parameters (GP2DS), fixed hyperparameters (GPFixed), and hyperparameters obtained by forwarding variable selection. the use of ML techniques enhances the screening paradigm in the first stages of medication R&D with numerou(GPFVS) and rescaled procedure (GPRFVS), as well as by conjugate gradient optimisation (GPOPT));These in silico models showed superior predictability to in-vitro tests. As a result, the use of ML techniques enhances the screening paradigm in the first stages of medication R&D with numerous advantages. [20]

Decoding empaglifozin's molecular mechanism of action in heart failure with preserved ejection fraction using artifcial intelligence:

Sodium-glucose co-transporter 2 inhibitors are being studied for the treatment of heart failure with preserved ejection fraction (HFpEF), however it is not understood how they work exactly. Here, our goal was to apply artificial intelligence (AI) to describe the molecular basis of empaglifozin's activity in HFpEF. We retrieved data on empaglifozin target information and biofags, together with information on HFpEF pathophysiological themes and differentially expressed genes/proteins, from specialized publically accessible sources. [21]

Deep learning AI and artificial neural networks were utilized to simulate the molecular effects of empaglifozin in HFpEF. According to the model, empagliflozin could undo 59% of the protein changes discovered in HFpEF. Inhibition of NHE1 (Na+/H+ exchanger 1) appeared to be the primary mechanism by which empaglifozin's effects in HFpEF were mediated, with SGLT2 appearing to play a less significant role. The chemical mechanism of action explanation was 94% accurate. Empaglifozin's pharmacological activity predominantly affected cardiomyocyte oxidative stress regulation and significantly influenced

heart concentric hypertrophy, systemic inflammation, myocardial extracellular matrix remodeling, and cardiomyocyte stiffness. These findings suggest empaglifozin's possible application in HFpEF. [22]

Nearly half of all cases of heart failure (HF) are currently heart failure with preserved ejection fraction (HFpEF), and no evidence-based treatment has been shown to enhance outcomes. The current treatment for heart failure with reduced ejection fraction (HEpEF) is based on modulating neurohormonal activation, which involves limiting excessive renin-angiotensin-aldosterone and sympathetic nervous system activation and boosting the body's endogenous natriuretic peptide defenses. patient's lowering plasma concentrations of NOS2, the NLPR3 infammasome, and TGF-1 over the course of a year of empagliflozin medication were used to validate these in silico results in vivo. [23] We discovered via AI modeling that the primary effect of empagliflozin in the therapy of HFpEF is exerted via NHE1 and is focused on the control of cardiomyocyte oxidative stress.

These findings suggest empaglifozin's possible application in HFpEF.Nearly half of all cases of heart failure (HF) are currently heart failure with preserved ejection fraction (HFpEF), and no evidence-based treatment has been shown to enhance outcomes. The current treatment for heart failure with reduced ejection fraction (HFrEF) is based on modulating neurohormonal activation, which involves limiting excessive renin-angiotensin-aldosterone and sympathetic nervous system activation and boosting the body's endogenous natriuretic peptide defenses. However, in numerous important HFpEF1-3 experiments, such tactics did not fare as well.A novel family of medications called sodium-glucose co-transporter 2 inhibitors (SGLT2i) is being studied for use in HF. Two expedited landmark clinical trials, the DAPA-HF with dapaglifozin4 and the Emperor-Reduced with empaglifozin5, have produced better than expected clinical benefits in HFrEF, with and without diabetes. Both dapaglifozin and empaglifozin are now undergoing pivotal clinical trials in HEpEF.The proximal renal tubule's SGLT2 receptor is blocked as part of SGLT2i's mechanism of action. 90% of glucose reabsorption into the bloodstream is carried out by SGLT2 receptors, and their blockage causes glycosuria and lower glycemic levels [6,7]. But SGLT2i-induced glycaemic control by itself seems to be effective.

Cardiovascular disease and type 2 diabetes together increase the chance of death. Type 2 diabetes is a major risk factor for cardiovascular disease. [24] There is insufficient proof that reducing blood sugar lowers the incidence of cardiovascular disease and death, although long-term follow-up studies may reveal a small cardiovascular benefit. [25] Additionally, there is worry that aggressive glucose reduction or the use of particular glucose-reducing medications may lead to unfavorable cardiovascular outcomes. [8] The advantages of glucose-lowering medications for cardiovascular safety must therefore be established.

Because sodium-glucose cotransporter 2 inhibitors increase urine glucose excretion by reducing renal glucose reabsorption, they lower the rates of hyperglycemia in people with type 2 diabetes.10 A medication for type 2 diabetes called empagliflozin is a specific inhibitor of sodium glucose cotransporter 211.12 The medication is claimed to lower glycated hemoglobin levels in individuals with type 2 diabetes, including those with stage 2 or 3a chronic renal disease, whether given as either a monotherapy or as an add-on therapy.13-20 Empagliflozin is also linked to decreased blood pressure and weight loss without an increase in heart rate.13-20 13-19 Both levels of low-density lipoprotein (LDL)14 and high-density lipoprotein (HDL) cholesterol have been shown to rise in response to empagliflozin.13-16 Urinary tract infection and vaginal infection are two of empagliflozin's most frequent adverse reactions. Additionally, empagliflozin is beneficial for indices of vascular resistance and arterial stiffness, as well as visceral obesity, albuminuria, and plasma urate. [26]

MECHANISM OF ACTION ELUCIDATION:

NN-based prediction revealed that the activity of empagliflozin in HFpEF would primarily occur through inhibition of NHE1 (Na+/H+ exchanger 1), with less prominent roles played by the other targets (SGLT2 and NHE3) (Table 1). Notably, NHE1 is the only target protein of empagliflozin that is expressed in cardiomyocytes and vascular cells.Analysis of the AI mathematical models elucidated a cascade of the molecular interactions and key proteins most likely involved in the therapeutic efects of empagliflozin in HFpEF NHE1 (Na+/H+ exchanger 1) inhibition was predicted to be the primary mechanism of empagliflozin's action in HFpEF, with other mechanisms playing less significant roles. SGLT2 and NHE3 were the additional targets (Table 1). It's noteworthy that NHE1 is the single target protein. with empagli-fozin that is expressed in vascular and cardiomyocyte cells.A cascade of molecular interactions and their relationships were revealed by analysis of the AI mathematical models. vital proteins most likely a factor in how well empagliflozin treats HFpEF. With a mean accuracy of 94%, the most likely mechanism of action was identified from a collection of 250 physiologically plausible possibilities. A number of significant conclusions can be drawn from Fig. 4.

Figure 4- Graphical representation of the identified MOA of empagliflozin in HFpEF

Figure 2. Graphical representation of the identified mechanism of action of empagliflozin in HFpEF. These paths were predicted by mathematical modelling, and biologically contextualized. Green lines indicate activations; red lines indicate inhibition; and blue lines indicate either activation or inhibition (cell-dependent effect). Broken lines show nodes that contain more than one protein, all of which participate in the mechanism of action in the same way.

First off, it seems that one unique effect of empagliflozin is the modulation of oxidative stress mechanisms (an upstream event in the development of HFpEF), via the cardiomyocyte-expressed target NHE1 through a variety of effectors, including AKTs (RAC- alpha/beta/gamma serine/threonine-protein kinases), nuclear factors of activated T-cells signaling (NFATs), and nitric oxide synthase (NOS2). Second, it is obvious that the mechanism of action of empagliflozin has a significant negative impact on systemic inflammation. Tumor necrosis factor- (TNF-), interleukin-1 (IL-1), intercellular adhesion molecule-1 (ICAM1), and the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome were among the proteins altered by this drug in our simulation, which decreased inflammation. Last but not least, we saw significant alteration of cardio-myocyte stiffness, myocardial extracellular matrix remodeling, and heart-concentric hypertrophy processes downstream of empagliflozin-mediated NHE1 inhibition. Vascular endothelial growth factor A (VEGFA), NF-B-induced collagen alpha-1 chain (CO1A1), transforming growth factor (TGF)-1, NFATs, and interleukin-10 (IL-10) are the mediators of these empagliflozin-inhibited myocardial changes. These events were identified in the models as the more indirect effects of NHE1 inhibition on oxidative stress. [27]

ARTIFICIAL INTELLIENCE MODELLING:

Modes:

Artificial neural networks (ANNs). ANNs are supervised. Algorithms that identify relationships between proteins (e.g. drug targets) and clinical elements of a network47, by inferring the probability that a specific relationship exists between two or more protein sets. The system attempts to find the shortest distance between two evaluated protein sets, thus generating a list of proteins ranked by their association with the defined pathophysiology. In this study, ANNs were used for the following analyses:

(1) Comparison of individual targets of empagliflozin in HFpEF (as a whole) and in each pathophysiological motif; synthetic neural networks (ANNs). ANNs are managed. Methods that determine connections between proteins (such as drug targets) and network clinical components47, by inferring Calculate the likelihood that a specific association between two or more protein sets exists. It system endeavors to Find the distance that separates two protein sets that have been analyzed in order to create a list of proteins according to their relationship to the defined pathology. ANNs were employed in this study for the following tasks:

(1) Analyses comparison of empagliflozin's specific goals in HFpEF (generally) and in each physiopathological theme

 (2) Identifying the biomarkers of empagliflozin in HFpEF; and

(3) comparing the efficacy of empagliflozin to other medications that have been studied in HFpEF (ACEI, ARBs, beta-blockers, MRA, ARNI), including analyses of each medication's relationship to the disease. Models in mathematics. In order to replicate the behavior of HFpEF and the projected effects of empagliflozin, in terms of changes in protein activity within the human protein network, we lastly created mathematical models that combined all relevant biological and pharmacological knowledge. Briefly, the actions listed below were done.

First, input models were produced using data on empagliflozin, HfpEF, and the protein/gene connections found in open-access databases. These models were used to assess how the signaling cascade was affected by the inhibition or activation of one or more nodes within the protein network. Second, output models were created using experimental RNA sequence data (upregulated or downregulated genes/proteins) to provide detailed and precise information about the disorders to the mathematical models. The complex protein network interaction structure and network activation signal flow were modeled using cutting-edge AI technology. [28] These included stochastic techniques like Simulated Annealing and Monte Carlo911, genetic algorithms, ANNs, dimensionality reduction techniques, and statistical pattern recognition technologies. Two distinct types of analysis were carried out by use of advanced AI:

(1) Estimating the therapeutic potency of empagliflozin in HFpEF (details are available in the online supplemental material.

(2) Creating an in-depth explanation of the molecular mechanisms behind empaglifozin's mechanism of action. To guarantee portrayal of the proteins most affected by empaglifozin in HfpEF, the graphical representation was watched carefully. This approach ensured detailed observation of the drug's downstream effects on the various HfpEF mechanisms.

The intensity of the reaction:
The term "intensity" of the response is used to quantify and assess the impact of a certain mechanism of action. The amount of protein effectors or motivations (#Ef) achieving the anticipated signal to ameliorate a disease is defined as the intensity in this research. We determined the number of effectors reaching the expected signal (#Ef) by assuming y_i as the value attained by a protein effector "i," v_i as its expected effector sign (active or inactive), and n as the overall number of effectors described for a phenotypic (HFpEF). The effects of a medication (empagliflozin) are anticipated to reverse a disease's phenotype. As a result, a medication should activate the inactive protein effectors of a pathogen while inactivating the active ones. However, the number of pathology-related effectors achieving an output signal with the polarity opposite to that defined in the condition characterization is what is being counted. Using Dirac's d (d(0)=1, otherwise 0, zero).

ARTIFICIAL INTELLIGENE IN CLINICAL RESEARCH AND TRIALS:
Living in the modern lifespan can result in the daily production of vast amounts of medical data. The use of artificial intelligence (AI) in pharmaceutical science, particularly pharmacological research, has grown in recent years. It helps in the analysis of preclinical (laboratory animals) and clinical (in humans) trial data. AI has been used in the evaluation of biomarkers and diseases. AI provides the best approach for a better healthcare system. AI and ML are helping to manage the best healthcare options for physicians, consumers, insurers, and regulators.

The academic community, research and development (R&D) organizations, industrial units, clinical settings, and community pharmacies are just a few of the sources from which data is collected. A better choice to coordinate the vast amounts of healthcare data and enhance the healthcare system and therapies is provided by AI and ML. [29]

The pharmaceutical sciences are greatly impacted by AI/ML. When compared to traditional technologies, the use of numerous analytical techniques including magnetic resonance imaging (MRI), X-ray, electrocardiogram (ECG), and histopathological imaging yields more accurate results with the aid of variable sensor and data acquisition systems.

In the process of inventing drugs, synthesizing chemicals, and analyzing biological test results, it has been hoped that creative collaboration between the mind and machine will lead to better decisions. The general process of developing an AI model for drug discovery involves four steps: first, defining the problem, whether it be specific or general, second, selecting an appropriate AI algorithm, and third, preparing input data that are satisfactory in terms of quality and quantity, representation characteristic, and fitting proportion. Finally, the model training and evaluation. [30]

The pharmaceutical sector has approached excellent platforms of AI technologies for drug repurposing for mixed data sources such as PREDICT, Netlap RLS, and DTINet. The majority of research that has been published so far has used learning algorithms to make precise predictions based on establishing a significant association between the medications, the targets, and the disease.

AI is employed at many levels of preclinical testing and data collection in the drug development process. AI is also utilized to forecast the efficacy, pharmacokinetics, and safety of medicinal molecules. AI is also employed in pharmaceutical sciences for production procedures, combination studies, and drug targeting studies.

Various methods of artificial Intelligence are as follows-
1) MRI, X-ray, ECG
2) NLP

3) LSSVM
4) PSOWNN
5) EPNN
6) GLCM
7) NN/XY-Fusion
8) QSAR
9) GAN, DNDD
10) BBPs, ACPs
11) NMR
12) DNNs, ANNs, RFs, and SVMs, k-NN
13) VigiGrade, VigiRank
14) CMap, GWAS
15) LapRLS

The use of artificial intelligence (AI) for healthcare purposes has constantly increased, and pharmacology has seen a wide range of applications. Modern pharmacology research and clinical practice incorporate AI at every stage, from early drug discovery to in-depth data mining.

By examining the chemical structure and properties, AI may be used to aid in the selection of the compounds that have the best chance of being successful. To begin with, if the target is known, AI can be used to foretell the kinds of chemical structures that might attach to the target in the intended manner. The chemical makeup of well-known, effective medications or endogenic agents can also be utilized to pinpoint targets and reveal the details of potential pharmacological targets. Last but not least, an understanding of known medicinal molecules, pharmacokinetics (PKs), and pharmacodynamics can be used to anticipate the in vivo properties of a novel compound. [31]

The selection of patients who match the eligibility requirements and are most likely to engage can be improved with the use of AI systems, which can process vast amounts of EHR data. As a result, less time and money are wasted trying to find patients. Second, AI can support trial-related patient monitoring.

Utilizing digital twins, AI can be used to predict a patient's response to medicine in traditional clinical trials and data mining. In virtual clinical trials AI-based decision support tools that can be thought of as medical devices will begin to see use in clinical pharmacology.

REFERENCES:
1. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. (2004). Artificial intelligence in medicine. Annals of the Royal College of Surgeons of England. 86(5):334.
2. Gómez-González E, Gomez E, Márquez-Rivas J, Guerrero-Claro M, Fernández-Lizaranzu I, Relimpio-López MI, Dorado ME, Mayorga-Buiza MJ, Izquierdo-Ayuso G, Capitán-Morales L. (2020). Artificial intelligence in medicine and healthcare: a review and classification of current and near-future applications and their ethical and social Impact. arXiv preprint arXiv:2001.09778.
3. Punn M, Bhalla N. (2013). Classification of wheat grains using machine algorithms. International Journal of Science and Research (IJSR). ;2(8):363-6.
4. Oke SA. (2008). A literature review on artificial intelligence. International journal of information and management sciences. 1;19(4):535-70.
5. Briganti G, Le Moine O.(2020). Artificial intelligence in medicine: today and tomorrow. Frontiers in medicine. 5;7:27.
6. Mesko B. (2020). Artificial intelligence will redesign healthcare. Medical Futurist.
7. Manne R, Kantheti SC. (2021). Application of artificial intelligence in healthcare: chances and challenges. Current Journal of Applied Science and Technology. 24;40(6):78-89.
8. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. (2004). Artificial intelligence in medicine. Annals of the Royal College of Surgeons of England.;86(5):334
9. Turing AM. Computing machinery and intelligence (1950). The Essential Turing: the Ideas That Gave Birth to the Computer Age. 2012:433-64.
10. Flaxman AD, Vos T. (2018). Machine learning in population health: opportunities and threats. PLoS medicine.;15(11):e1002702.
11. Yin Z, Yao C, Zhang L, Qi S. (2023). Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect. Frontiers in Medicine. 8;10:1128084.
12. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH. (2019). Artificial intelligence in cancer imaging: clinical challenges and applications. CA: a cancer journal for clinicians. ;69(2):127-57
13. Thakur N, Yoon H, Chong Y. (2020). Current trends of artificial intelligence for colorectal cancer pathology image analysis: a systematic review. Cancers.13;12(7):1884.
14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 71(3):209-49.

15. Lu Y, Xin D, Wang F. (2019). Predictive significance of preoperative systemic immune-inflammation index determination in postoperative liver metastasis of colorectal cancer. OncoTargets and therapy. 20:7791-9.

16. Joseph DA, Meester RG, Zauber AG,Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M. (2016). Colorectal cancer screening: estimated future colonoscopy need and current volume and capacity. Cancer. 15;122(16):2479-86.

17. Bayes-Genis A, Iborra-Egea O, Spitaleri G, Domingo M, Revuelta-López E, Codina P, Cediel G, Santiago-Vacas E, Cserkóová A, Pascual-Figal D, Núñez J. (2021). Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Scientific reports. 8;11(1):12025.

18. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 373(22):2117-28.

19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. (2008). Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine. 4;359(23):2456-67.

20. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 8;383(15):1413-24.

21. Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. (2018). Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Annals of translational medicine. ;6(23).109-113

22. Pitt, B. et al. (2014). TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–92.

23. Solomon, S. D. et al. (2019). PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with pre-served ejection fraction. N. Engl. J. Med. 381, 1609–1620.

24. Verma S, McMurray JJ. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. ;61:2108-17.

25. Chirinos JA. (2017). Deep phenotyping of systemic arterial hemodynamics in HFpEF (part 2): clinical and therapeutic considerations. Journal of cardiovascular translational research. ;10(3):261-74.

26. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. (2011). Epidemiology and clinical course of heart failure with preserved ejection fraction. European journal of heart failure. ;13(1):18-28.

27. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. (2011). Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. European journal of heart failure. ;13(9):1013-8.

28. Darmellah A, Rücker-Martin C, Feuvray D. (2009). ERM proteins mediate the effects of Na+/H+ exchanger (NHE1) activation in cardiac myocytes. Cardiovascular research. 1;81(2):294-300.

29. Alvarez BV, Villa-Abrille MC. (2013). Mitochondrial NHE1: a newly identified target to prevent heart disease. Frontiers in Physiology. 28;4:152.

30. Du Y, Zhu H, Li D, Wang L, Zhang L, Luo Y, Pan D, Huang M. (2014). Lentiviral-mediated overexpression of Akt1 reduces anoxia–reoxygenation injury in cardiomyocytes. Cell Biology International. ;38(4):488-96.

31. Zhavoronkov A, Vanhaelen Q, Oprea TI.(2020). Will artificial intelligence for drug discovery impact clinical pharmacology?. Clinical Pharmacology & Therapeutics. ;107(4):780-5.

32. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. (2023). Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 75(1):3-18.

33. Van der Lee M, Swen JJ.(2023). Artificial intelligence in pharmacology research and practice. Clinical and Translational Science. ;16(1):31-6.

34. Van Laar SA, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J. (2020). An electronic health record text mining tool to collect real-world drug treatment outcomes: a validation study in patients with metastatic renal cell carcinoma. Clinical Pharmacology & Therapeutics. ;108(3):644-52.

35. Noorbakhsh-Sabet N, Zand R, Zhang Y, Abedi V. (2019). Artificial intelligence transforms the future of health care. The American journal of medicine. 1;132(7):795-801.

36. Mak KK, Balijepalli MK, Pichika MR. (2022). Success stories of AI in drug discovery-where do things stand?. Expert opinion on drug discovery. ;17(1):79-92.

37. Chaturvedula A, Calad-Thomson S, Liu C, Sale M, Gattu N, Goyal N. (2019). Artificial intelligence and pharmacometrics: time to embrace, capitalize, and advance?. CPT: pharmacometrics & systems pharmacology. ;8(7):440.

38. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. (2023). Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. ;75(1):3-18.

39. Jabeen A, Ranganathan S. (2019). Applications of machine learning in GPCR bioactive ligand discovery. Current opinion in structural biology. 1;55:66-76.

40. Bertucci F, Le Corroller-Soriano AG, Monneur A, Fluzin S, Viens P, Maraninchi D, Gonçalves A. Santé (2020). cancer hors les murs», Big Data et intelligence artificially. Bulletin du cancer. 1;107(1):102-12.

41. Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care?. Journal of translational medicine. 2019 Dec;17:1-28.

42. Alhussein M, Muhammad G, Hossain MS. (2019). EEG pathology detection based on deep learning. IEEE Access. 224;7:27781-8.

43. Jain R, Sontisirikit S, Iamsirithaworn S, Prendinger H. (2019). Prediction of dengue outbreaks based on disease surveillance, meteorological and socio-economic data. BMC infectious diseases. 19(1):1-6.

44. Aronson JK. (2010). A manifesto for clinical pharmacology from principles to practice. British journal of clinical pharmacology. ;70(1):3.

45. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. (2017). A comprehensive map of molecular drug targets. Nature reviews Drug discovery. 16(1):19-34.

46. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. (2011). Too many roads not taken. Nature. 470(7333):163-5.

47. Sun Y, Barber R, Gupta M, Aggarwal CC, Han J. (2011). Co-author relationship prediction in heterogeneous bibliographic networks. In2011 International Conference on Advances in Social Networks Analysis and Mining : (pp. 121-128). IEEE.

48. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. (2023). Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. ;75(1):3-18.

49. Gul F, Mir I, Rahiman W, Islam TU. (2021). Novel implementation of multi-robot space exploration utilizing coordinated multi-robot exploration and frequency modified whale optimization algorithm. IEEE Access.1;9:22774-87.

50. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. (2023). Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. ;75(1):3-18.

51. Jaiswal P, Mandal M, Mishra A. (2020). Effect of hesperidin on fluoride-induced neurobehavioral and biochemical changes in rats. Journal of Biochemical and Molecular Toxicology. 34(11):e22575.

52. Ghosh S, Singh A. (2020). The scope of Artificial Intelligence in mankind: A detailed review. InJournal of Physics: Conference Series ; Vol. 1531, No. 1, p. 012045). IOP Publishing.

53. Van der Lee M, Allard WG, Bollen S, Santen GW, Ruivenkamp CA, Hoffer MJ, Kriek M, Guchelaar HJ, Anvar SY, Swen JJ. (2020). Repurposing of diagnostic whole exome sequencing data of 1,583 individuals for clinical pharmacogenetics. Clinical Pharmacology & Therapeutics. ;107(3):617-27.

54. Sharma S, Shukla A, Tiwari R. (2016). Multi robot area exploration using nature inspired algorithm. Biologically Inspired Cognitive Architectures.1;18:80-94.

CITATION OF THIS ARTICLE

Jyoti Jawale, Diksha Shinde, Shalaka Kunjir, Sejal Dorage, Shraddha Randhwan, Shraddha Tapkir, Shrungar Randhir, Sayali Gaikwad, Shivani Kholam. A Brief Review on Artificial Intelligence in Pharmacology. Bull. Env. Pharmacol. Life Sci., Spl Issue [2]: 2023: 513-523.